From IgAN to FSGS: Translating Recent Successes & Lessons Learned to Beyond IgAN
Time: 9:30 am
day: Pre-Conference Focus Day
Details:
- Discuss how the FDA approval of sparsentan (Filspari) for IgA Nephropathy serves as a model for accelerating treatment development in other glomerular diseases, particularly FSGS
- Explore the ongoing FSGS trials and how lessons from the IgAN journey are being integrated to optimize clinical trial design and endpoint selection for rare glomerular diseases
- Highlight the role of regulatory pathways and approval frameworks in facilitating faster access to treatments in both IgAN and FSGS, including navigating accelerated approval requirements